162 related articles for article (PubMed ID: 31173472)
1. Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients.
Mora B; Rumi E; Guglielmelli P; Barraco D; Maffioli M; Rambaldi A; Caramella M; Komrokji R; Gotlib J; Kiladjian JJ; Cervantes F; Devos T; Palandri F; De Stefano V; Ruggeri M; Silver RT; Benevolo G; Albano F; Cavalloni C; Pietra D; Barbui T; Rotunno G; Cazzola M; Vannucchi AM; Giorgino T; Passamonti F
Cancer Med; 2019 Aug; 8(9):4089-4092. PubMed ID: 31173472
[TBL] [Abstract][Full Text] [Related]
2. Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study
Palandri F; Palumbo GA; Iurlo A; Polverelli N; Benevolo G; Breccia M; Abruzzese E; Tiribelli M; Bonifacio M; Tieghi A; Isidori A; Martino B; Sgherza N; D'Adda M; Bergamaschi M; Crugnola M; Cavazzini F; Bosi C; Binotto G; Auteri G; Latagliata R; Ibatici A; Scaffidi L; Penna D; Cattaneo D; Soci F; Trawinska M; Russo D; Cuneo A; Semenzato G; Di Raimondo F; Aversa F; Lemoli RM; Heidel F; Reggiani MLB; Bartoletti D; Cavo M; Catani L; Vianelli N
Semin Hematol; 2018 Oct; 55(4):248-255. PubMed ID: 30502854
[TBL] [Abstract][Full Text] [Related]
3. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union.
Moulard O; Mehta J; Fryzek J; Olivares R; Iqbal U; Mesa RA
Eur J Haematol; 2014 Apr; 92(4):289-97. PubMed ID: 24372927
[TBL] [Abstract][Full Text] [Related]
4. Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey.
Mesa RA; Miller CB; Thyne M; Mangan J; Goldberger S; Fazal S; Ma X; Wilson W; Paranagama DC; Dubinski DG; Naim A; Parasuraman S; Boyle J; Mascarenhas JO
Cancer; 2017 Feb; 123(3):449-458. PubMed ID: 27690182
[TBL] [Abstract][Full Text] [Related]
5. Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients.
Mora B; Guglielmelli P; Kuykendall A; Rumi E; Maffioli M; Palandri F; De Stefano V; Caramella M; Salmoiraghi S; Kiladjian JJ; Gotlib J; Iurlo A; Cervantes F; Ruggeri M; Silver RT; Albano F; Benevolo G; Ross DM; Della Porta MG; Devos T; Rotunno G; Komrokji RS; Casetti IC; Merli M; Brociner M; Caramazza D; Auteri G; Barbui T; Cattaneo D; Bertù L; Arcaini L; Vannucchi AM; Passamonti F
Leukemia; 2022 Oct; 36(10):2453-2460. PubMed ID: 36042316
[TBL] [Abstract][Full Text] [Related]
6. Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011.
Deadmond MA; Smith-Gagen JA
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2131-8. PubMed ID: 25968903
[TBL] [Abstract][Full Text] [Related]
7. Incidence of myeloproliferative neoplasms in Calgary, Alberta, Canada.
Heppner J; Nguyen LT; Guo M; Naugler C; Rashid-Kolvear F
BMC Res Notes; 2019 May; 12(1):286. PubMed ID: 31126326
[TBL] [Abstract][Full Text] [Related]
8. Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States.
Verstovsek S; Yu J; Scherber RM; Verma S; Dieyi C; Chen CC; Parasuraman S
Leuk Lymphoma; 2022 Mar; 63(3):694-702. PubMed ID: 34689695
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Dynamic International Prognostic Scoring System and MYelofibrosis SECondary to PV and ET Prognostic Model for Prediction of Outcome in Polycythemia Vera and Essential Thrombocythemia Myelofibrosis after Allogeneic Stem Cell Transplantation.
Gagelmann N; Eikema DJ; de Wreede LC; Koster L; Wolschke C; Arnold R; Kanz L; McQuaker G; Marchand T; Socié G; Bourhis JH; Mohty M; Cornelissen JJ; Chevallier P; Bernasconi P; Stelljes M; Rohrlich PS; Fanin R; Finke J; Maertens J; Blaise D; Itälä-Remes M; Labussière-Wallet H; Robin M; McLornan D; Chalandon Y; Yakoub-Agha I; Kröger N;
Biol Blood Marrow Transplant; 2019 Jun; 25(6):e204-e208. PubMed ID: 30930192
[TBL] [Abstract][Full Text] [Related]
10. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden.
Landgren O; Goldin LR; Kristinsson SY; Helgadottir EA; Samuelsson J; Björkholm M
Blood; 2008 Sep; 112(6):2199-204. PubMed ID: 18451307
[TBL] [Abstract][Full Text] [Related]
11. How common are myeloproliferative neoplasms? A systematic review and meta-analysis.
Titmarsh GJ; Duncombe AS; McMullin MF; O'Rorke M; Mesa R; De Vocht F; Horan S; Fritschi L; Clarke M; Anderson LA
Am J Hematol; 2014 Jun; 89(6):581-7. PubMed ID: 24971434
[TBL] [Abstract][Full Text] [Related]
12. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.
Passamonti F; Giorgino T; Mora B; Guglielmelli P; Rumi E; Maffioli M; Rambaldi A; Caramella M; Komrokji R; Gotlib J; Kiladjian JJ; Cervantes F; Devos T; Palandri F; De Stefano V; Ruggeri M; Silver RT; Benevolo G; Albano F; Caramazza D; Merli M; Pietra D; Casalone R; Rotunno G; Barbui T; Cazzola M; Vannucchi AM
Leukemia; 2017 Dec; 31(12):2726-2731. PubMed ID: 28561069
[TBL] [Abstract][Full Text] [Related]
13. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
Zhan H; Spivak JL
Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
[TBL] [Abstract][Full Text] [Related]
14. A population-based study of outcomes in polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the United States from 2001 to 2015: Comparison with data from a Mayo Clinic single institutional series.
Smith CJ; Thomas JW; Ruan G; Hyun MC; Bansal R; McLaughlin N; Pardanani A; Gangat N; Go RS; Szuber N; Goyal G; Shah MV; Tefferi A
Am J Hematol; 2021 Dec; 96(12):E464-E468. PubMed ID: 34661932
[No Abstract] [Full Text] [Related]
15. Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors.
Cerquozzi S; Tefferi A
Blood Cancer J; 2015 Nov; 5(11):e366. PubMed ID: 26565403
[TBL] [Abstract][Full Text] [Related]
16. Epidemiology of the myeloproliferative disorders: essential thrombocythaemia, polycythaemia vera and idiopathic myelofibrosis.
Kutti J; Ridell B
Pathol Biol (Paris); 2001 Mar; 49(2):164-6. PubMed ID: 11317963
[TBL] [Abstract][Full Text] [Related]
17. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms.
Boddu P; Masarova L; Verstovsek S; Strati P; Kantarjian H; Cortes J; Estrov Z; Pierce S; Pemmaraju N
Ann Hematol; 2018 Jan; 97(1):109-121. PubMed ID: 29143068
[TBL] [Abstract][Full Text] [Related]
18. Secondary solid tumors and lymphoma in patients with essential thrombocythemia and polycythemia vera - single center experience.
Masarova L; Cherry M; Newberry KJ; Estrov Z; Cortes JE; Kantarjian HM; Verstovsek S
Leuk Lymphoma; 2016; 57(1):237-9. PubMed ID: 25904378
[No Abstract] [Full Text] [Related]
19. Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies.
Sekhri R; Sadjadian P; Becker T; Kolatzki V; Huenerbein K; Meixner R; Marchi H; Wallmann R; Fuchs C; Griesshammer M; Wille K
Ann Hematol; 2021 Nov; 100(11):2707-2716. PubMed ID: 34462786
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the need for cytoreduction and its potential carcinogenicity in children and young adults with myeloproliferative neoplasms.
Choi HS; Hong J; Hwang SM; Lee JH; Ma Y; Kim SA; Lee JY; Lee JO; Bang SM
Ann Hematol; 2021 Oct; 100(10):2567-2574. PubMed ID: 34331110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
